Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IKK16 | IKK | NFKB | 1.8767 | 3.1049 | 3.8519 | -0.9668 | -0.9445 | -0.8619 | -0.9890 | -0.9578 | -0.8641 | 2.2018 | 3.4729 | 4.3592 | 0.3739 | 0.4332 | 0.4763 | 3.1521 | 4.0389 | 4.8853 | |
Sunitinib | PDGFR/VEGFR/KIT/FLT3 | RTK | 4.8478 | 6.2817 | 9.9436 | -0.9902 | -0.9623 | -0.8818 | -0.9966 | -0.9683 | -0.8864 | 1.4527 | 2.4005 | 3.5359 | 0.3679 | 0.4354 | 0.4695 | 8.0047 | 9.6271 | 12.8243 | |
Ispinesib | KSP | Kinesin | 0.0263 | 0.0439 | 0.1261 | -0.9817 | -0.9567 | -0.8688 | -1.0000 | -0.9800 | -0.6258 | 0.4997 | 1.2912 | 3.1780 | 0.5293 | 0.6720 | 0.8104 | 0.0357 | 0.4315 | 1.3590 | |
Imatinib | ABL/KIT/PDGFR | nRTK | 18.5481 | 21.7914 | 25.5570 | -0.9852 | -0.9632 | -0.8948 | -0.9969 | -0.9814 | -0.8936 | 2.2328 | 2.7060 | 3.3541 | 0.3997 | 0.4467 | 0.4851 | 27.9144 | 31.9309 | 36.9254 | |
Oxamflatin | HDAC | HDAC | 0.6664 | 0.9513 | 1.6592 | -0.9525 | -0.8858 | -0.8199 | -1.0000 | -0.9857 | -0.8929 | 1.0334 | 1.2610 | 1.4776 | 0.4375 | 0.5175 | 0.6006 | 1.6681 | 2.6703 | 3.8183 | |
NU6102 | CDK1/2 | CDK | 12.2242 | 17.3275 | 31.6450 | -0.7759 | -0.4783 | -0.1439 | -1.0000 | -0.9972 | -0.6085 | 1.3221 | 1.8051 | 3.6950 | 0.1178 | 0.1554 | 0.2440 | 20.2928 | 27.4520 | 55.8294 | |
Tozasertib | AURK/FLT3/ABL/JAK2 | AURK | 0.9523 | 4.3787 | 11.8540 | -0.5661 | -0.3376 | -0.0359 | -1.0000 | -1.0000 | -0.4350 | 0.4858 | 0.8218 | 1.3502 | 0.1794 | 0.3014 | 0.3656 | 4.7346 | 16.5294 | 34.8041 | |
Oxaliplatin | DNA cross-linker | DNA cross-linker | 3.2681 | 4.9333 | 12.0662 | -0.9391 | -0.8084 | -0.7104 | -1.0000 | -1.0000 | -0.9516 | 0.6228 | 0.7486 | 1.0057 | 0.4005 | 0.5419 | 0.5768 | 14.7918 | 22.6957 | 42.6124 | |
Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.2491 | 0.7096 | 1.5478 | -0.9565 | -0.8762 | -0.7290 | -1.0000 | -1.0000 | -0.9202 | 0.6212 | 0.8572 | 1.4388 | 0.3615 | 0.4228 | 0.5481 | 1.3258 | 2.5025 | 5.3389 | |
Everolimus | MTOR | MTOR | 0.0432 | 0.6717 | 4.3873 | -0.8294 | -0.6714 | -0.2303 | -1.0000 | -1.0000 | -0.6838 | 0.2890 | 0.4230 | 0.7677 | 0.3295 | 0.4415 | 0.5925 | 1.5205 | 9.7227 | 26.2255 | |
Temsirolimus | MTOR | MTOR | 0.1192 | 1.7003 | 10.0307 | -0.9332 | -0.8176 | -0.6679 | -1.0000 | -1.0000 | -0.9967 | 0.2520 | 0.4363 | 1.0813 | 0.3951 | 0.4933 | 0.6311 | 6.4751 | 18.8586 | 43.0334 | |
Afatinib | EGFR/HER2 | ErbB | 0.1253 | 1.5517 | 2.4757 | -0.9553 | -0.9200 | -0.8460 | -1.0000 | -1.0000 | -0.9391 | 0.5080 | 1.0283 | 1.7263 | 0.4620 | 0.5435 | 0.6679 | 1.1116 | 3.3143 | 4.9447 | |
GSK1070916 | AURK | AURK | 0.6046 | 3.0981 | 6.6549 | -0.8474 | -0.6391 | -0.3610 | -1.0000 | -1.0000 | -0.9999 | 0.6499 | 0.9902 | 1.5949 | 0.2113 | 0.2924 | 0.4314 | 3.5405 | 8.2453 | 15.6107 | |
Nelfinavir | N/A | N/A | 8.4034 | 9.7440 | 15.4339 | -0.8211 | -0.6445 | -0.2989 | -1.0000 | -1.0000 | -0.8006 | 1.6805 | 2.3548 | 2.7767 | 0.1130 | 0.1589 | 0.1970 | 12.4011 | 15.3815 | 22.7642 | |
Sigma A6730 | AKT | AKT | 2.0327 | 6.5660 | 11.2198 | -0.9178 | -0.8320 | -0.6777 | -1.0000 | -1.0000 | -0.9546 | 0.9310 | 1.3794 | 2.0044 | 0.2439 | 0.2875 | 0.4042 | 6.3004 | 13.6236 | 19.0461 |